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Background and objective: Some patients continue taking their medication as prescribed 
despite serious financial pressures, while others with the ability to pay forego treatment due to cost 
concerns. The primary goal of this study was to explore how patients’ beliefs about the necessity 
of treatment and treatment side effects, influence cost-related non-adherence (CRN).
Methods: 27,302 participants in the Harris Interactive Chronic Illness Panel completed 
an internet survey. The current study focused on two subsamples representing: (a) the most 
economically-vulnerable survey respondents (ie, individuals with household incomes of 
US$25,000 per year or less and monthly out-of-pocket medication costs of at least US$60, 
n = 1321); and (b) respondents who were the most likely to have the financial resources to 
pay for medications (ie, those with incomes of US$125,000 or more and monthly medication 
costs of less than US$60.00, n = 1195). Multivariate models were constructed for each group 
to determine the independent impact on CRN of perceived need for medications and side-
effect concerns. Increased risk for CRN associated with depression and asthma diagnoses 
also was examined.
Results: Twenty-one percent of economically vulnerable respondents reported continuing to 
take their medication as prescribed despite serious cost pressures, while 14% of high-income 
respondents reported CRN despite apparently manageable out-of-pocket costs. Both low 
  perceived need for medications and concerns about side-effects affected CRN risk in low-income 
and high-income groups. Within groups of both low-income and high-income respondents, 
depression and asthma significantly increased patients’ odds of reporting CRN.
Conclusion: Beyond objective financial measures, CRN is influenced by patient beliefs, which 
can influence the perceived value of prescription drugs. Addressing these beliefs, as well as the 
unique adherence concerns of patients with depression and asthma, could decrease CRN rates 
even if cost pressures themselves cannot be reduced.
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Introduction
Objective financial measures, such as income or out-of-pocket (OOP) copayment 
costs, explain only a minority of the variance in cost-related non-adherence (CRN) 
behavior. Some patients are sensitive to OOP medication cost changes even when 
those changes are modest, while many patients continue to report that they do not 
reduce their medication due to cost concerns, even when they have a limited ability 
to pay for treatment.1–3
Possible modifiers of patients’ risk for CRN include diagnoses, medication-
related beliefs, and communication patterns with clinicians about medications.4 Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Concerns about medication side-effects have been cited as 
a cause of intentional non-adherence,5–7 and low-income 
patients often express concerns about the perceived need for 
their medication as well as potential adverse effects.8 Other 
studies confirm that both perceived need and side-effect 
concerns may affect overall medication adherence.9–13 Few 
prior studies have directly looked at the relationship between 
perceived risks and benefits of therapy as determinants of 
CRN.14 Studies addressing this association suggest that 
factors such as patient-clinician communication patterns15–17 
and an overall depressive mood18 can influence adherence 
when patients are facing financial pressures. Most prior 
studies examining the influence of these beliefs on CRN 
have averaged effects across a broad spectrum of patients 
with diverse financial resources. Such studies leave questions 
unanswered about the ways in which mutable cofactors (such 
as patient health beliefs) influence CRN behaviors differently 
among patients with low incomes, compared with those who 
have the resources to pay for their prescription drugs.
Understanding modifiable co-factors for CRN among 
low-income and high-income individuals with chronic 
diseases is important for several reasons. If beliefs affecting 
patients’ valuation of their treatments play an important role 
for low-income patients, it may be possible to reduce CRN 
behavior even if patients’ ability to pay cannot be improved. 
Moreover, by estimating the proportion of higher-income 
patients reporting CRN and the non-cost factors determining 
that behavior, we can begin to estimate the proportion of 
the CRN among low-income patients that would remain 
if incomes were raised or medication benefit programs 
expanded. Finally, both low-income and high-income 
patients who report non-adherence due to “cost” may be 
expressing more general concerns about their treatment that 
could be addressed through improved patient education and 
open discussion about their medication’s necessity or risk 
of side-effects.
The purpose of the current study was to understand the 
health beliefs that modify patients’ risk for CRN using a 
large national survey of patients with serious chronic health 
problems. We focused on influences of patients’ CRN within 
two subgroups representing the greatest and least OOP 
medication cost pressures: individuals with low incomes 
and relatively high OOP costs, and individuals with high 
incomes and relatively low OOP costs. Within each group, 
we examined patients’ perceived need for medication as well 
as their concerns about side effects as two possible influences 
on their likelihood of forgoing treatment due to cost concerns. 
We also examined the independent contribution to CRN 
of two chronic diseases with symptom-based treatments 
(depression and asthma) which have been associated with 
higher CRN risk in prior studies.19,20 Our hypothesis was 
that – even in groups at the extremes of the distribution in 
terms of medication cost pressures – medication beliefs and 
symptom-based treatment issues play important and roughly 
consistent roles in patients’ CRN.
Methods
study population
The study was approved by the George Mason University 
Institutional Review Board. Study participants were part of 
the Harris Interactive Chronic Illness Panel (CIP), which 
is a national, internet-based panel of adults with chronic 
diseases. CIP participants are recruited through postal mail 
invitations, TV advertisements, telephone recruitment for 
under-represented populations, email, and websites, eg, social 
media sites, news sites, search engine sites, and community 
portals. Panel recruitment efforts are focused on maintaining 
a representative sample of the general population as well as 
identifying and reaching under-represented groups.
In February and March of 2009, randomly selected mem-
bers of the CIP were sent an e-mail invitation to participate in 
the survey. Panel members were eligible for participation if 
they were aged 40 and older, resided in the US, and reported 
one of six chronic diseases prevalent among US adults: 
hypertension, hyperlipidemia, diabetes, asthma, osteoporo-
sis, and depression. Of the 51,774 CIP panel members who 
were US residents aged 40 or older and who completed the 
chronic-disease screener, 27,302 persons with chronic dis-
eases (53%) completed the survey. CIP members who were 
successfully contacted were more likely than members who 
were not reached, to be aged 50 or older, male, white, college 
educated, and of higher income (all P , 0.0001).
We used self-reported income and OOP medication cost 
data to identify two contrasting groups with respect to their 
potential ability to pay for prescription medication. The 
first group represented the most economically-vulnerable 
respondents, ie, those reporting annual household incomes 
of US$25,000 or less and monthly OOP medication costs of 
US$60.00 or higher. OOP payments were used as the measure 
of cost pressures rather than information about patients’ 
drug coverage because: (1) details about individual benefit 
packages in this national survey were not available; (2) OOP 
payments represent the net impact of any pharmacy benefit 
respondents may have had; (3) OOP payments are a more 
direct determinant of individuals’ CRN. The second subgroup 
represented economically-advantaged individuals, ie, those Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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who reported an annual household income of US$125,000 or 
more and relatively low OOP medication costs of US$60.00 
per month or less. The US$60.00 cut-off was chosen because 
it approximated the median of the OOP medication cost 
distribution. The findings presented here were not sensitive 
to other cut-offs for OOP medication costs (see auxiliary 
analyses presented below).
Measures
Data about participants’ sociodemographic characteristics 
(age, gender, educational attainment, and race/ethnicity) were 
available from information they provided when enrolling in 
the CIP. Participants responded to a series of CRN questions 
regarding strategies adults use to reduce medication use in 
order to minimize out-of-pocket costs. Items were adapted 
based on measures in prior surveys conducted by the 
Medicare Current Beneficiary Survey, the AARP (formally 
known as the American Association of Retired Persons), the 
Kaiser Family Foundation, and other groups.12,16,21–29 The 
role of cost in patients’ adherence behavior was emphasized 
using the question stem: “In 2008, because of the cost of 
all of [your] prescription medications…” Questions asked 
respondents about the frequency with which they engaged 
in six cost-reducing strategies including: “I delayed a new 
prescription fill because I couldn’t afford it,” “I took fewer 
pills than prescribed or skipped doses in order to make the 
prescription last longer,” and “I stopped taking one or more 
of my prescription drugs altogether because I could not 
afford them.” The frequency of each cost-reducing strategy 
was measured using a five-point scale ranging from “Yes, 
very often” to “No, never.” For analyses presented here, we 
created a binary measure for any reported CRN across the 
6 behaviors. We also created separate measures representing: 
(a) CRN behavior that involved decreasing the frequency of 
adherence, ie, “took fewer pills or skipped doses,” “delayed 
filling a new/existing prescription” and “split pills in half to 
make them last longer”; and (b) not taking a medication at 
all, ie, “stopped taking a prescription altogether” or “did not 
fill a new prescription because I could not afford it.”
Patients’ beliefs about their medication were reported 
using a series of questions asking about respondents’: 
perceived need for medication (ten items), concerns 
about side-effects (six items), and perceived information/
knowledge about their prescriptions (four items). The medi-
cation belief questions were answered specific to the condi-
tion for which the respondent was enrolled in the sample. For 
example, patients whose index condition was diabetes were 
asked about their beliefs about their “  diabetes”   medication. 
Participants responded to belief items using a six-point Lik-
ert scale from “agree completely” to “disagree completely.” 
We created summary measures for beliefs about medication 
necessity, side-effects, and perceived information by aver-
aging item responses within that domain. Alpha reliability 
measures for the summary scores were each 0.90 or higher. 
To provide more interpretable odds ratios in the multivari-
ate logistic models, summary scores were categorized into 
tertiles (eg, a low, moderate, or high-level of side-effect 
concern).
Analysis
Initial analyses focused on differences between low-income/
high-OOP and high-income/low-OOP groups in respondents’ 
demographic characteristics, chronic diseases, CRN behav-
iors, and medication beliefs. Multivariate logistic models 
were fit within each group to determine the independent effect 
of medication beliefs, controlling for patients’ age, gender, 
and educational attainment. Initial multivariate models 
included the three trichotomized measures of health beliefs 
(perceived need, side-effects, and knowledge). Knowledge 
scores had no independent effect on CRN and were dropped 
from subsequent analyses. Each model also included indica-
tors for the 6 chronic diseases defining patients’ eligibility 
for the survey. As predicted by prior research,20,30–32 the two 
symptomatic chronic diseases, depression and asthma, were 
associated with substantially higher rates of CRN and were 
retained in the final models. Controls for confounding in 
each model included patients’ age, gender, and educational 
attainment.
Results
sample description and crn behaviors
The sample was predominately white with a mean age of 
60 (Table 1). Low-income respondents were more than 
twice as likely as high-income respondents to be female 
and were less than one-third as likely to have a college 
degree. Low-income respondents were substantially sicker 
on average: 64% reported fair or poor health (compared to 
15% of respondents with high incomes and low costs), 40% 
of low-income respondents reported taking four or more 
prescriptions (compared to 13% of respondents with high 
incomes and low cost), and substantially more low-income 
than high-income respondents reported asthma (26% vs 
11%), depression (44% vs 14%), diabetes (36% vs 18%), 
and osteoporosis (18% vs 7%, all P , 0.001).
Overall 79% of low-income respondents with high 
OOP medication costs reported some CRN, while the Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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remaining 21% did not report modifying their adherence 
despite their limited ability to pay (Table 2). As expected, 
significantly fewer high-income respondents with low 
OOP costs reported CRN, although 14% still reported 
cutting-back on their medication due to cost concerns. 
Low-income respondents reported a variety of strategies to 
avoid medication costs including delaying a prescription fill 
(72%), stopping a prescription all-together (48%), and not 
filling a new prescription at all (59%). The most common 
CRN behavior among high-income respondents was 
splitting pills or taking fewer doses to make a prescription 
last longer (11%).
Differences across income groups  
in beliefs about medications
A substantial number of all respondents either “agreed” 
or “strongly agreed” with beliefs about the prescription 
medication prescribed for their index condition that could 
affect their risk for CRN. Low-income respondents were less 
likely than high-income respondents to agree that they needed 
their medication, with fewer agreeing that the medication 
would improve their condition (64% vs 75%, P , 0.001) 
or that the benefits of the medication outweighed the risks 
(62% vs 73%, P , 0.001). Despite using more medications, 
low-income respondents were somewhat less likely than 
high-income respondents to report that they were well 
informed about the prescription medication related to their 
index disease (69% vs 74%, P , 0.001). Substantially more 
low-income than high-income respondents reported that they 
worried about the side-effects of their prescriptions (20% vs 
10%, P , 0.001), and more than three times as many low-
income respondents agreed that they are likely to experience 
negative side effects from their medications (17% vs 5%, 
P , 0.001). With respect to summary scores, high-income 
patients on average reported higher medication need, greater 
knowledge about their treatments, and fewer concerns about 
medication side-effects (each P , 0.05).
impact of health beliefs on crn 
behaviors
In multivariate models among respondents with low 
incomes and high OOP costs, respondents with the lowest 
perceived need for their medication had 50% greater odds 
of CRN than patients with the greatest perceived need 
(Table 3, adjusted odds ratio [AOR]: 1.5, 95% CI: 1.2–1.8). 
Independent of perceived need and other covariates, low-
income respondents with high OOP costs had 80% greater 
odds of CRN if they had a high level of side-effect concerns 
(AOR: 1.8, 95% CI: 1.2–2.8). Perceived need played an 
even larger role in the CRN behaviors of respondents with 
higher incomes and relatively manageable OOP medication 
costs. In this group, respondents reporting low perceived 
need for their medication were 2.1 times as likely to report 
CRN as those with high perceived need (95% CI: 1.3–3.4). 
Among high-income/low-OOP respondents, those reporting 
a high level of side-effect concerns had 2.3 times odds 
of CRN as those with low concerns (95% CI: 1.4–3.7). 
Depression and asthma influenced CRN decisions for both 
Table 1 Patient characteristics
Low income  
high OOP
High income  
low OOP
P-value
n 1,321 1,195
Age (mean, sD) 60.5, 9.6 59.5, 8.8 0.007
Female (%) 67.3 33.8 ,0.001
White (%) 93.4 93.7 0.77
college degree (%) 23.4 74.7 ,0.001
employment status (%) ,0.001
employed 21.8 59.2
retired 35.8 26.4
Unemployed 42.3 14.4
Fair/poor health (%) 64.4 15.3 ,0.001
number of rx (%) ,0.001
1 22.2 39.8
2 20.8 30.4
3 17.5 16.6
4+ 39.5 13.2
chronic diseases (%)
Asthma 26.4 10.5 ,0.001
hypertension 63.6 67.1 0.07
Depression 44.3 14.1 ,0.001
Diabetes 36.2 18.4 ,0.001
hyperlipidemia 44.9 38.8 0.002
Osteoporosis 18.3 7.3 ,0.001
Note: Percents are column percents.
Abbreviations: OOP, out-of-pocket medication costs; Rx, prescriptions. 
Table 2 Cost-related non-adherence (CRN) behaviors
Low income  
high OOP
High income  
low OOP
P-value
Any crn (%) 79.0 14.4 ,0.001
Delaying
Delayed filling a  
prescription (%)
72.0 6.5 ,0.001
split pills/take  
fewer doses (%)
64.1 11.0 ,0.001
Stopping
stopped taking rx  
altogether (%)
47.9 2.5 ,0.001
Did not fill a  
prescription at all (%)
59.3 3.5 ,0.001
Note: Percents are column percents.
Abbreviations: OOP, out-of-pocket medication costs; Rx, prescriptions. Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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low-income/high-OOP respondents and those with high 
incomes/low OOP.
The overall pattern shown in Table 3 was observed 
both for CRN behaviors involving taking less medication 
as well as those involving either stopping a medication all-
together or failing to fill a prescription at all (Table 4). In 
general,   perceived need and side effect concerns   influenced 
both types of CRN behaviors in the low-income and 
  high-income groups. Depression was associated with a 
significantly increased risk of CRN among both low-income 
and high-income respondents. Asthma diagnosis also was 
associated with a substantially increased risk, particularly 
among   participants with high incomes and relatively low 
OOP costs.
Auxiliary analyses
As noted in the Methods, participants reported CRN behavior 
with respect to all of the medication in their regimen, while 
medication beliefs questions focused on their main diagnosis 
determining eligibility for the study. In auxiliary analyses, 
we re-fit each model within the subset of respondents with 
no more than four medications, ie, those for whom a larger 
proportion of their regimen was targeted to their index 
chronic disease. Overall findings were similar to those 
presented here.
As noted earlier, we used US$60.00 per month to define 
groups “high” vs “low” monthly medication costs. The 
pattern of effects presented here was not sensitive to other 
cut-offs in the range of US$40 to “greater than US$100” 
per month. For example, among low-income patients with 
monthly OOP costs in excess of US$100 (n = 931), patients 
with the greatest concerns about side-effects had twice the 
odds of CRN as other low-income patients (AOR: 2.0, 95% 
CI: 1.2–3.2), controlling for the covariates show in Table 3. 
In that same subsample, depression was associated with a 
40% increased odds of CRN, and asthma was associated 
with a 60% increased odds (both P , 0.05). We conclude 
that even at very high levels of cost pressures, non-cost 
factors   continue to influence low-income patients’ risk of 
“cost-related” medication underuse.
Although the main purpose of choosing these two sub-
groups was to explore the impact of health beliefs in groups 
with very different cost pressures, in additional analyses 
exploring other combinations of income and OOP costs, we 
observed similar findings. For example, perceived need and 
side-effect concerns also played a similar role as determinants 
of patients’ risk of CRN among patients with low incomes and 
low OOP costs, as well as among patients with high incomes 
and high (.US$100 per month) OOP costs.
Discussion
“Have nots” who bear medication costs 
and “haves” who report CRN
While most respondents with household incomes of 
US$25,000 or less and relatively high OOP   medication 
Table  3  Adjusted  odds  ratios  predicting  overall  cost-related 
non-adherence
Low income  
high OOP
High income   
low OOP
Medication beliefs
need (moderate) 1.1 1.9**
(0.8, 1.7) (1.2, 3.0)
need (low) 1.5** 2.1**
(1.2, 1.8) (1.3, 3.4)
side effects (moderate) 1.4* 1.3
(1.0, 2.1) (0.9, 1.9)
side effects (high) 1.8** 2.3**
(1.2, 2.8) (1.4, 3.7)
Diagnoses
Depression 1.8** 2.0**
(1.3, 2.5) (1.3, 2.9)
Asthma 1.6** 2.0**
(1.1, 2.3) (1.3, 3.2)
Pseudo R-square 0.10 0.12
Note: Models controlled for patients’ age, gender, and educational attainment.   
*P , 0.05; **P , 0.01.
Abbreviations: OOP, out-of-pocket medication costs; Rx, prescriptions.
Table  4  Adjusted  odds  ratios  predicting  cost-related  non-
adherence by subtype
Slow Stop
Low  
income  
high OOP
High  
income  
low OOP
Low  
income  
high OOP
High  
income  
low OOP
Medication beliefs
need (moderate) 1.3 2.0** 1.1 1.6
(0.9, 1.9) (1.3, 3.3) (0.8, 1.6) (0.7, 3.8)
need (low) 1.5** 2.2** 1.4* 2.5*
(1.2, 1.9) (1.3, 3.6) (1.0, 2.0) (1.1, 5.8)
side effects 
(moderate)
1.4*
(1.0, 2.0)
1.3
(0.9, 1.9)
1.1
(0.8, 1.5)
1.0
(0.5, 2.0)
side effects (high) 1.7** 2.4** 1.8** 2.0*
(1.1, 2.5) (1.5, 3.8) (1.3, 2.6) (1.0, 4.4)
Diagnoses
Depression 1.8** 1.9** 1.4** 2.2*
(1.3, 2.4) (1.3, 2.9) (1.1, 1.9) (1.1, 4.1)
Asthma 1.5* 2.0** 1.5** 2.1**
(1.0, 2.2) (1.3, 3.1) (1.1, 2.0) (1.1, 4.1)
Pseudo R-square 0.10 0.12 0.12 0.12
Notes: slow = cost-related non-adherence involving taking less of ongoing prescriptions 
by (eg, taking fewer pills or delaying the time until refill); Stop = not filling a prescription 
at all due to cost concerns or stopping medication use completely. Models controlled 
for patients’ age, gender, and educational attainment. *P , 0.05; **P , 0.01.
Abbreviations: OOP, out-of-pocket medication costs; Rx, prescriptions. Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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costs reported CRN, 21% continued to take their medica-
tion as prescribed despite cost pressures. Cost pressures 
were significantly less for participants with incomes of 
US$125,000 or more (2.5 times the national median) and 
lower OOP medical costs. Nevertheless, 14% of this group 
still reported some cost-related non-adherence.
What factors modify patients’ response 
to cost pressures?
Results from the current study demonstrate that factors 
affecting patients’ valuation of their medication – particularly 
their beliefs about their medication’s necessity as well as 
concerns about side effects – influenced their decisions to 
forgo treatment in the context of cost pressures. Among 
patients with low incomes and high costs, both perceived 
need and side- effect concerns can tip the scales toward CRN. 
These beliefs play similar roles in the adherence decisions 
of individuals with a substantially greater ability to pay for 
their treatment. Overall, these findings suggest that decisions 
about non-adherence due to cost are influenced by some 
of the same determinants that influence non-cost-related 
adherence behaviors. Factors such as the patient’s perceived 
susceptibility to disease complications, the medication’s 
perceived efficacy, and the perceived link between medication 
use and side effects all play a role in patients’ choice to forgo 
treatment when faced with cost pressures.9
Patients’ beliefs about their medications’ necessity and 
side-effect profile can be addressed in multiple ways. Many 
patients with chronic illnesses are prescribed more medica-
tion than is appropriate, providing little added benefit to jus-
tify the increased OOP costs and associated risk of drug–drug 
interactions.33 Prescribers should carefully consider patients’ 
regimen in its entirety and ensure that all pharmacotherapy 
is justified both clinically and in terms of the costs that 
patients must bear. Patients may be more likely to question 
a medication’s importance for their health if they lack trust 
in their prescriber or have poor communication with that 
clinician.16,17 Raising issues such as potential medication 
benefits or side-effect concerns may improve that level of 
trust and consequently increase patients’ willingness to take 
their medication as prescribed despite cost pressures.
Depression and asthma diagnoses played significant roles 
in determining CRN for both low-income and high-income 
respondents. Pessimism about the future and fatalism about 
one’s ability to control outcomes are hallmarks of depression, 
and this study suggests that those cognitions may increase 
patients’ risk of forgoing treatment due to concerns about 
the value of their treatment. Primary care providers should 
consider targeting patients with depression for more explicit 
conversations about medication cost concerns. More gen-
erally, these results highlight the importance of treating 
patients’ depression effectively through counseling, phar-
macologic management, or both.34–36 One study has shown 
that Medicare patients on inhaler medications for chronic 
pulmonary disease may be at higher risk of CRN than patients 
using other medications.37 Other studies confirm that costs 
play a role in asthma treatment adherence, although it is 
likely that costs interplay with other characteristics of the 
regimen in influencing patients’ behavior.38,39 Given that 
patients with more severe asthma are also more likely to 
suffer depressive symptoms,40 greater attention to the ways 
in which patients with these chronic illnesses make decisions 
about adherence when facing out-of-pocket costs should be 
a priority for research.
how valid are these comparisons  
of CRN between the “haves”  
and “have nots”?
As shown in Table 1, low-income and high-income groups in 
the current study were very different on multiple dimensions 
including their sociodemographic characteristics, medication 
use, and diagnoses. Other factors, such as patients’ health 
literacy levels,41 undoubtedly also vary across the groups and 
may have a strong impact on health beliefs and CRN. In the 
current study, we have addressed these differences in three 
ways: (a) by controlling for gender, age, diagnoses, and edu-
cational attainment in multivariate models; (b) by conducting 
auxiliary analyses that examined the relationships of interest 
within the subgroup of respondents on no more than four 
medications; and (c) by examining the relationships of interest 
using other cut-offs for OOP costs and using other combina-
tions of cost and income (eg, within the subgroup of patients 
with high incomes and high costs). Nevertheless, residual 
differences in health literacy, disease severity and other fac-
tors likely remain. Despite these measured and unmeasured 
differences between the income groups, both perceived need 
and side-effect concerns played consistent and largely similar 
roles in patients’ CRN. We believe that this is one of the most 
important and striking findings from this study, and that it is 
one which is valid despite the study’s limitations.
Limitations and conclusions
While data were drawn from a large, national sample, 
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survey (specifically lower-income patients, those with lower 
health literacy levels, and those more likely to be racial/
ethnic minorities) may differ with respect to the influence 
that their health beliefs have on their risk for CRN. Beliefs 
questions in this study focused on the main condition 
for which patients were identified, while CRN questions 
focused more broadly on patients’ overall non-adherence 
due to cost concerns. Initial analyses found little variation in 
CRN independently associated with asymptomatic chronic 
conditions, and controlling for depression and asthma 
minimized the potential confounding effect of diagnosis on 
the beliefs-CRN relationship. Overall, variation in patients’ 
beliefs across different medications in their regimen would 
tend to lessen the magnitude of the relationships observed, 
suggesting that perceived medication necessity and side-
effect concerns may play an even larger role in CRN than 
what is suggested here. Other medication beliefs besides 
those related to treatment necessity or side-effects may also 
play a role in patients’ risk for CRN. For example, patients 
may find their medication-taking inconvenient or that their 
medication use draws attention to their illness in a way that 
adversely affects their self-image. Finally, the relationship 
between patients’ beliefs and CRN may differ for patients 
with other chronic diseases not captured in the current study, 
such as patients with irritable bowel disease, chronic low 
back pain, or HIV/AIDS. Future studies, including those 
using qualitative methods, those with objective measures 
of patients’ adherence behavior and prescription drug costs, 
and those including some of the conditions mentioned above 
would be useful to explore more fully the ways in which 
patients’ beliefs impact their willingness to pay for their 
prescription medications.
In sum, this study suggests that even at the extremes of 
the continuum representing patients with a high degree and 
low degree of medication cost pressures, there is substantial 
variation in patients’ adherence. CRN decisions in both of 
these groups are influenced by non-cost factors, including 
patients’ concerns about the necessity of their treatment and 
side-effects. Depression and asthma diagnoses also influences 
patients’ risk for CRN, independent of costs, these beliefs, 
and sociodemographic covariates. While efforts to increase 
the affordability of essential medications remains critically 
important, addressing these beliefs as well as the unique 
issues among patients with symptom-based regimens also 
should be the focus of efforts to prevent CRN.
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